Form 4: Eli Lilly Director J. Erik Fyrwald Acquires Shares

Director J. Erik Fyrwald of Eli Lilly & Co. acquired shares of common stock on November 18, 2024.

Summary

• J. Erik Fyrwald, a director at Eli Lilly & Co., acquired shares of common stock.
• The transaction occurred on November 18, 2024.
• The acquisition involved 320.53 shares at a price of $727.2 per share.
• Following the transaction, Fyrwald's total holdings amount to 72,540.938 shares.
• The reported transaction includes 18 shares received in distributions in August 2024.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a routine transaction by a company director. While insider buying can be seen as a positive signal, it is not a significant event on its own.

Positives

• The acquisition of shares by a director may signal confidence in the company's future performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for directors to buy or sell shares in their company, and these transactions are required to be disclosed to the SEC.

Comparison to Industry Standards

• This type of filing is standard practice for publicly traded companies in the United States.
• Directors and officers are required to report their transactions in company stock to the SEC within two business days.
• The reporting requirements are designed to ensure transparency and prevent insider trading.

Stakeholder Impact

• The share acquisition may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Eli Lilly, LLY, Director, Share Acquisition, Insider Trading, SEC Form 4, J. Erik Fyrwald